Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 582 for:    bilirubin AND liver function

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01894243
Recruitment Status : Completed
First Posted : July 10, 2013
Last Update Posted : April 14, 2017
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow patients with mild or moderate hepatic impairment or normal hepatic function continued access to olaparib after the PK phase and will provide additional safety data.

Condition or disease Intervention/treatment Phase
Solid Tumours Drug: Olaparib tablet dosing Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment
Actual Study Start Date : March 13, 2014
Actual Primary Completion Date : December 1, 2016
Actual Study Completion Date : March 30, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Olaparib

Arm Intervention/treatment
Normal hepatic function

Patients with:

(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN

Drug: Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Mild hepatic impairment
As defined by the Child-Pugh Classification System.
Drug: Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd

Moderate hepatic impairment
As defined by the Child-Pugh Classification System.
Drug: Olaparib tablet dosing
Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd




Primary Outcome Measures :
  1. Pharmacokinetics of olaparib: maximum olaparib concentration (Cmax) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: maximum plasma concentration (Cmax). Pharmacokinetics will not be measured in Part B

  2. Pharmacokinetics of olaparib: time to maximum concentration (tmax) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: time to reach maximum plasma concentration (tmax). Pharmacokinetics will not be measured in Part B

  3. Pharmacokinetics of olaparib: area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-t) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: area under the plasma concentration-time curve from zero to the last measurable time point (AUC0-t). Pharmacokinetics will not be measured in Part B

  4. Pharmacokinetics of olaparib: area under the plasma concentration-time curve from zero to infinity (AUC) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: area under the plasma concentration-time curve from zero to infinity (AUC). Pharmacokinetics will not be measured in Part B

  5. Pharmacokinetics of olaparib: apparent plasma clearance following oral administration (CL/F) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: apparent plasma clearance following oral administration (CL/F). Pharmacokinetics will not be measured in Part B

  6. Pharmacokinetics of olaparib: terminal half-life (t½) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: terminal half-life (t½). Pharmacokinetics will not be measured in Part B

  7. Pharmacokinetics of olaparib : apparent volume of distribution (Vz/F) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: apparent volume of distribution (Vz/F). Pharmacokinetics will not be measured in Part B

  8. Pharmacokinetics of olaparib : terminal rate constant (λz) [ Time Frame: Blood samples will be collected on Day 1 of Part A at these timepoints: pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,24,48,72 and 96 hours post-dose. ]
    In Part A, the following variable will be calculated for olaparib where the data allow: terminal rate constant (λz). Pharmacokinetics will not be measured in Part B


Secondary Outcome Measures :
  1. Determine safety and tolerability of olaparib by recording adverse events [ Time Frame: From baseline, every visit until 30 days after last dose, assessed up to 20 months. ]
    Assessment of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v4.0

  2. Determine safety and tolerability of olaparib by assessment of 12 lead Electrocardiograms [ Time Frame: FPart A: baseline, days 1 and 3. Part B: Day 1 then every 4 weeks. Final assessment within 30 days after last dose. ]
    Assessment of standard 12 lead electrocardiograms (ECGs)

  3. Determine safety and tolerability of olaparib by physical examination [ Time Frame: Part A: baseline, day -1 and within 30 days after last dose. Part B: Day 1. ]
    Assessment of physical examination

  4. Determine safety and tolerability of olaparib by assessment of vital signs [ Time Frame: Part A: baseline, days 1,2 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. ]
    Assessment of standard vital signs (including blood pressure, pulse)

  5. Determine safety and tolerability of olaparib by assessment of body temperature [ Time Frame: Part A: baseline, day 1. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. ]
    Assessment of standard vital signs (body temperature)

  6. Determine safety and tolerability of olaparib by assessment of clinical chemistry results [ Time Frame: Part A: baseline, days -1 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. ]
    Assessment of laboratory parameters (clinical chemistry)

  7. Determine safety and tolerability of olaparib by assessment of haematology results [ Time Frame: Part A: baseline, days -1 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. ]
    Assessment of laboratory parameters (haematology)

  8. Determine safety and tolerability of olaparib by assessment of urinalysis results [ Time Frame: Part A: baseline, days -1 and 3. Part B: Days 1,8,15,22,29 then every 4 weeks. Final assessment within 30 days after last dose. ]
    Assessment of laboratory parameters (urinalysis)


Other Outcome Measures:
  1. Changes in plasma protein binding of olaparib and subsequent effects on pharmacokinetics: free maximum plasma concentration of unbound olaparib (Cmax) [ Time Frame: 1 hour post olaparib dose blood sample ]
    In Part A, plasma protein binding at 1 hour after dosing, used to calculate free Cmax (Cmax of unbound olaparib)

  2. Changes in plasma protein binding of olaparib and subsequent effects on pharmacokinetics: free area under the plasma concentration-time curve from zero to infinity of unbound olaparib (AUC) [ Time Frame: 1 hour post olaparib dose blood sample ]
    In Part A, plasma protein binding at 1 hour after dosing, used to calculate free area under the plasma concentration-time curve from zero to infinity (AUC)

  3. Changes in plasma protein binding of olaparib and subsequent effects on pharmacokinetics: free apparent plasma clearance of unbound olaparib (CL/F) [ Time Frame: 1 hour post olaparib dose blood sample ]
    In Part A, plasma protein binding at 1 hour after dosing, used to calculate free apparent plasma clearance following oral administration (CL/F)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:-

For inclusion in the study as a patient with hepatic impairment, the following criterion must be met:

  1. Patients must have stable mild hepatic impairment (as defined by Child-Pugh classification), for at least 1 month prior to the start of the study or stable moderate hepatic impairment ( as defined by Child Pugh classification) for at least 2 weeks prior to the start of the study. Patients with hepatic metastases and/or HCC are eligible for the study, providing the hepatic metastases or HCC are not the sole reason for any changes in liver function satisfying the criteria for mild or moderate hepatic impairment as defined by the Child Pugh criteria. Patients must have globally impaired hepatic function to participate in the study. For inclusion in the study as a patient with normal hepatic function, the following criteria must be met:
  2. Negative result for serum hepatitis B surface antigen and hepatitis C antibody.
  3. Total bilirubin less than or equal to1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy.
  4. Aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) less than or equal to 2.5 x institutional ULN unless liver metastases are present in which case it must be less than or equal to 5 x ULN. All patients must fulfil the following criteria:
  5. Provision of written informed consent prior to any study specific procedures.
  6. Patients must be greater than or equal to18 years of age.
  7. Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy or for which no suitable effective standard therapy exists. In case of HCC, histological or cytological confirmation is not required in the following situations, as per international guidelines of the scientific societies European Society for Medical Oncology (ESMO) and

    American Association for the Study of Liver Diseases (AASLD):

    • Nodules >2 cm with a typical feature of HCC on a dynamic imaging technique, or any nodule associated with α-fetoprotein (AFP) concentration >400 ng/ml or rising AFP on sequential determinations, do not require biopsy but should be considered as proven HCC (Jelic et al 2010).
    • Nodules >1 cm found on ultrasound screening of a cirrhotic liver should be investigated further with either 4-phase multi-detector CT scan or dynamic contrast enhanced MRI. If the appearances are typical of HCC (ie, hyper-vascular in the arterial phase with washout in the portal venous or delayed phase), the lesion should be treated as HCC. If the findings are not characteristic or the vascular profile is not typical, a second contrastenhanced study with the other imaging modality should be performed, or the lesion should be biopsied (level II) (Bruix et al 2011).
  8. Normal organ and bone marrow function measured within 28 days prior to administration of IP as defined below: Haemoglobin greater than or equal to 9.0 g/dL, with no blood transfusions in the previous 28 days.

    Absolute neutrophil count (ANC) greater than or equal to1.5 x 109/L. White blood cells (WBC) greater than 3 x 109/L. Platelet count greater than or equal to 75 x 109/L. Serum creatinine less than or equal to1.5 x institutional ULN.

  9. Calculated serum creatinine clearance greater than 50 mL/min (using Cockcroft-Gault formula or by 24-hour urine collection).
  10. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  11. Patients must have a life expectancy greater than or equal to 8 weeks.
  12. Evidence of non childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day 1 of the first treatment period in Part A. Postmenopausal is defined as:

    Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments.

    Luteinising hormone and follicle-stimulating hormone levels in the postmenopausal range for women under 50 years of age.

    Radiation-induced oophorectomy with last menses greater than 1 year ago. Chemotherapy-induced menopause with greater than 1 year interval since last menses.

    Surgical sterilisation (bilateral oophorectomy or hysterectomy).

  13. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
  14. Patients must be on a stable concomitant medication regimen (with the exception of electrolyte supplements), defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.

Exclusion criteria:-

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).
  2. Previous enrolment in the present study.
  3. Treatment with any investigational product (IP) during the last 14 days (or a longer period depending on the defined characteristics of the agent used).
  4. Treatment in the previous 3 months before dosing in this study with any drug known to have a well defined potential for hepatoxicity (eg, halothane).
  5. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 2 weeks prior to study treatment. The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment.
  6. Patients who have received or are receiving inhibitors or inducers of CYP3A4 within the washout period.
  7. Toxicities (greater than or equal to CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.
  8. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. Patients with asymptomatic brain metastases or with symptomatic but stable brain metastases can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.
  9. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of major surgery.
  10. Patients considered a poor medical risk due to a serious uncontrolled medical disorder, non malignant systemic disease, uncontrolled seizures, or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive bilateral interstitial lung disease on high resolution computer tomography (HRCT) scan, or any psychiatric disorder that prohibits obtaining informed consent.
  11. Patients with a history of heart failure or left ventricular dysfunction.

2. Patients who have gastric, gastro-oesophageal or oesophageal cancer. 13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of olaparib.

14. Breastfeeding women. 15. Immunocompromised patients eg, patients who are known to be serologically positive for human immunodeficiency virus (HIV).

16. Patients with a known hypersensitivity to olaparib or any of the excipients of the product. 17. Resting ECG with measurable QTc greater than 470 msec on 2 or more time points within a 24 hour period or family history of long QT syndrome.

18. Clinical judgment by the investigator that the patient should not participate in the study. In addition to exclusion criteria 1 to 18, patients with normal hepatic function should not enter the study if the following exclusion criterion is fulfilled: 19. History or presence of hepatic disease known to interfere with the absorption, distribution, metabolism or excretion of olaparib. In addition to exclusion criteria 1 to 18, patients with mild or moderate hepatic impairment should not enter the study if the following exclusion criteria are fulfilled: 20. Patients with hepatic encephalopathy (as described in the Child Pugh Classification system).

21. Fluctuating or rapidly deteriorating hepatic function as indicated by widely varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period (eg, advanced ascites, fever, active gastrointestinal bleeding).

22. Change in dose regimen of medically required medication within the last 2 weeks before screening and/or the use of disallowed co-medication in the 3 weeks prior to admission to the clinic.

23. Presence of acute liver disease caused by drug toxicity or by an infection. 24. Severe portal hypertension or surgical porto-systemic shunts. 25. Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.

26. Oesophageal variceal bleeding within the past 2 months. 27. Anticoagulant therapy with warfarin or related coumarins.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01894243


Locations
Layout table for location information
Czech Republic
Research Site
Brno, Czech Republic
France
Research Site
Bordeaux Cedex, France
Research Site
Bordeaux, France
Research Site
Dijon, France
Research Site
Grenoble cedex 9, France
Research Site
Lyon Cedex 8, France
Research Site
Paris Cedex 13, France
Korea, Republic of
Research Site
Seoul, Korea, Republic of
Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Maastricht, Netherlands
United Kingdom
Research Site
London, United Kingdom
Research Site
Sutton, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Layout table for investigator information
Study Director: Anitra Fielding AstraZeneca Senior Research Physician
Principal Investigator: Christian Rolfo UZ Antwerpen

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01894243     History of Changes
Other Study ID Numbers: D0816C00005
2013-002246-37 ( EudraCT Number )
First Posted: July 10, 2013    Key Record Dates
Last Update Posted: April 14, 2017
Last Verified: April 2017

Keywords provided by AstraZeneca:
oncology,
cancer,
neoplasm,
anticancer drug,
pharmacokinetics,
area under curve,
olaparib,
solid tumour,
mild hepatic impairment,
moderate hepatic impairment

Additional relevant MeSH terms:
Layout table for MeSH terms
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents